Lanean...
Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: The assessment of the added therapeutic value of new medicines with a new active substance is hampered by the lack of appropriate comparative information. Though the extent of this information gap is generally perceived as substantial, it has not been quanti...
Gorde:
| Egile Nagusiak: | , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Blackwell Science Inc
2007
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2000577/ https://ncbi.nlm.nih.gov/pubmed/17166187 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2006.02812.x |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|